Effector Therapeutics, Inc.

Samuel Sperry

Siegfried Heinz Reich

Justin T Ernst

Paul A Sprengeler

Alan X Xiang

Stephen Evan Webber

Bennett C Borer

Jo Ann Z Wilson

Chinh Viet Tran

Garrick Kenneth Packard

Theo Michels

Christian Nilewski

Kaveri Urkalan

Mike Shaghafi

Alan Grubbs

Takasuke Mukaiyama

The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Crystalline forms of Mnk inhibitors

The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X, X, R, R, Rand n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

Piperidine-substituted Mnk inhibitors and methods related thereto

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.  For Formula I compounds X, X, X, X, X, X, Q, L, L, Y, R, R, R, R, R, R, R, Rand rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

EIF4E-inhibiting compounds and methods

The present invention provides crystalline solids of 6'-((6-aminopyrimidin-4-yl)amino)-8&#x2032;-methyl-2&#x2032;H-spiro[cyclohexane-1,3&#x2032;-imidazo[1,5-a]pyridine]-1&#x2032;,5&#x2032;-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Crystalline forms of MNK inhibitors

Growing community of inventors

Encinitas, CA, United States of America

Samuel Sperry